Risankizumab in the treatment of psoriasis - literature review

Risankizumab is a humanized, monoclonal antibody directed against subunit p19 of interleukin 23 (IL-23). In February 2019, risankizumab was approved for the treatment of moderate to severe psoriasis. The aim of the work is to collect up-to-date information on risankizumab and present its mechanism of action and recent clinical trials in which it was applied. This work also compares the mechanisms of action of risankizumab and ustekinumab and their importance in the treatment of psoriasis and describes the role of IL-23 in the etiopathogenesis of psoriasis. The work also refers to the effectiveness of risankizumab treatment and its safety profile. The results of molecular and histological studies that show changes in psoriatic skin after risankizumab treatment are also described.